HIV drug treatments have transformed the landscape of HIV management, extending life expectancy and reducing mortality. However, as individuals with HIV age, liver health challenges, particularly metabolic dysfunction-associated steatotic liver disease (MASLD) and non-alcoholic steatohepatitis (NASH), have emerged. Delve into the intricate relationship between antiretroviral therapy and liver conditions, exploring management strategies and alternative treatment options.
Understanding the Impact of HIV Drug Treatments on NASH
HIV drug treatments have revolutionized the management of HIV, significantly reducing AIDS-related mortality and increasing life expectancy among people living with HIV (PLWH). However, as this population ages, new health challenges have emerged, particularly concerning liver health. One such challenge is the development of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), which can progress to non-alcoholic steatohepatitis (NASH) (source).
The Role of Antiretroviral Therapy (ART)
Antiretroviral therapy (ART), especially the newer regimens, plays a crucial role in the development of liver conditions like MASLD and NASH. The switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF), often combined with integrase inhibitors (INSTIs), has been linked to increased insulin resistance. This metabolic disturbance can lead to the development of metabolic syndrome and eventually NASH (source). A German study found that individuals with HIV taking ART containing INSTIs or TAF are at a higher risk of developing fatty liver disease, with a significant number progressing to NASH (source).
Factors Contributing to Liver Disease in PLWH
The pathogenesis of MASLD in PLWH involves both common metabolic factors and HIV-specific factors. ART, particularly older generations, has been associated with liver steatosis and metabolic disturbances. Chronic immune activation and alterations in gut microbiota also contribute to liver disease in this population (source). Additionally, factors such as male sex, a body mass index (BMI) above 23 kg/m2, and type 2 diabetes have been significantly associated with the development and progression of steatosis (source).
Managing MASLD in PLWH
Managing MASLD in PLWH requires a holistic approach. Lifestyle modifications, including dietary changes and exercise, are crucial. A multidisciplinary team approach is recommended to address the complex interplay of factors contributing to liver disease in this population (source). Regular screenings, such as Fibroscan, are advised for individuals with a higher risk of liver damage, particularly those with a BMI above 23 or taking TAF or INSTIs (source).
Exploring Alternative ART Regimens
Research into alternative ART regimens has shown promising results. For instance, switching from Efavirenz (EFV) to Raltegravir (RAL) has been associated with reductions in hepatic steatosis. This is potentially due to the discontinuation of EFV’s mitochondrial toxicity and RAL’s metabolic-friendly properties (source). Such findings highlight the importance of considering the metabolic profiles of ART drugs when managing liver health in PLWH.
Why You Should Learn More About HIV Drug Treatments and NASH Today
Understanding the effects of HIV drug treatments on liver health is crucial for improving the quality of life for people living with HIV. As the population ages, the prevalence of liver diseases like MASLD and NASH is expected to rise, making it essential to explore effective management strategies. By staying informed about the latest research and treatment options, healthcare providers and patients can work together to mitigate the risks associated with ART and promote better liver health.